These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10981035)

  • 1. Current controversies in blood pressure in diabetic nephropathy.
    Ritz E; Schömig M
    Curr Hypertens Rep; 1999; 1(1):9-10. PubMed ID: 10981035
    [No Abstract]   [Full Text] [Related]  

  • 2. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Threatened diabetic nephropathy. Early administration of ACE inhibitors and AT1 blockers].
    Einecke U
    MMW Fortschr Med; 2002 Apr; 144(15):14. PubMed ID: 12004443
    [No Abstract]   [Full Text] [Related]  

  • 4. Unmet need in diabetic nephropathy: failed drugs or trials?
    de Zeeuw D; Heerspink HJL
    Lancet Diabetes Endocrinol; 2016 Aug; 4(8):638-640. PubMed ID: 27160545
    [No Abstract]   [Full Text] [Related]  

  • 5. Evolving strategies for renoprotection: diabetic nephropathy.
    Parving HH; Hovind P; Rossing K; Andersen S
    Curr Opin Nephrol Hypertens; 2001 Jul; 10(4):515-22. PubMed ID: 11458033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy.
    Andersen S; Schalkwijk CG; Stehouwer CD; Parving HH
    Diabetes Care; 2000 Jul; 23(7):1031-2. PubMed ID: 10895868
    [No Abstract]   [Full Text] [Related]  

  • 7. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
    Parving HH; Hovind P
    Curr Hypertens Rep; 2002 Oct; 4(5):387-93. PubMed ID: 12217258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy.
    Ruilope LM
    J Hypertens Suppl; 1995 Aug; 13(2):S91-3. PubMed ID: 8576796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive treatment in nephropathy of type II diabetes: role of the pharmacological blockade of the renin-angiotensin system.
    Rodby RA
    Nephrol Dial Transplant; 1997 Jun; 12(6):1095-6. PubMed ID: 9198032
    [No Abstract]   [Full Text] [Related]  

  • 10. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
    Eberhard R; Dikow R
    Ann Med; 2002; 34(7-8):507-13. PubMed ID: 12553490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H; Bakris GL
    Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.
    Lewis JB; Berl T; Bain RP; Rohde RD; Lewis EJ
    Am J Kidney Dis; 1999 Nov; 34(5):809-17. PubMed ID: 10561135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current update in the management of diabetic nephropathy.
    Van Buren PN; Toto R
    Curr Diabetes Rev; 2013 Jan; 9(1):62-77. PubMed ID: 23167665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Shimada N; Sekizuka K; Ebihara I; Takahashi Y; Tanaka A; Koide H
    Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibition in type I diabetic nephropathy.
    Lewis EJ
    Contrib Nephrol; 1996; 118():206-13. PubMed ID: 8744059
    [No Abstract]   [Full Text] [Related]  

  • 19. [Guidelines for the treatment of arterial hypertension in diabetes mellitus. The consensus recommendations of the German League for the Fight against High Blood Pressure, Inc., the German Diabetes Society and the Society for Nephrology].
    Schäfers RF; Lütkes P; Ritz E; Philipp T
    Dtsch Med Wochenschr; 1999 Nov; 124(45):1356-72. PubMed ID: 10592780
    [No Abstract]   [Full Text] [Related]  

  • 20. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.